Drug Discovery World

NOVEMBER 19, 2023

The post High Content Imaging and Flow Cytometry in Drug Discovery 2023 appeared first on Drug Discovery World (DDW).

Drugs 130

Drugs 130

Molecular Design

NOVEMBER 19, 2023

It’s now time to get back to chemical probes and I’ll be taking a look at S2023 (Systematic literature review reveals suboptimal use of chemical probes in cell-based biomedical research) which has already been reviewed in blog posts from Practical Fragments , In The Pipeline and the Institute of Cancer Research. Readers of this blog are aware that PAINS filters usually crop up in posts on chemical probes but there are other things that I want to discuss and, in any case, references to PAINS in S

Cell Based Assays 78

Cell Based Assays Research Compliance Laboratories 78

Drug Patent Watch

NOVEMBER 19, 2023

Annual Drug Patent Expirations for NUCYNTA+ER Nucynta Er is a drug marketed by Collegium Pharm Inc and is included in one NDA. It is available from one supplier. There are… The post New patent expiration for Collegium Pharm drug NUCYNTA ER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs Marketing 59

Drug Patent Watch

NOVEMBER 19, 2023

Annual Drug Patent Expirations for HYSINGLA+ER Hysingla Er is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from one supplier. There are… The post New patent expiration for Purdue Pharma drug HYSINGLA ER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs Marketing 59

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drug Patent Watch

NOVEMBER 19, 2023

Annual Drug Patent Expirations for OXYCONTIN Oxycontin is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from five suppliers. There are twenty-one… The post New patent expiration for Purdue Pharma drug OXYCONTIN appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs Marketing 59

Drug Patent Watch

NOVEMBER 19, 2023

Annual Drug Patent Expirations for OPANA+ER Opana Er is a drug marketed by Endo Pharms and is included in two NDAs. There are eleven patents protecting this drug and six… The post New patent expiration for Endo Pharms drug OPANA ER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

Drugs Marketing 59